Abstract: Objective: To evaluate the effects and safety of Oxaliplatin(LOHP) combined with Capecitabine(CAPE)in older patients with advanced gastric cardiac adenocarcinoma(GCA). Methods: Eighty patients with advanced GCA wereclassified into the older group (≥75 years) and the control group (<75 years). XELOX regimen was administered in bothgroups, i.e. LOHP 65 mg/m² iv infusion 2h on d1 and d8; CAPE 1000mg/m²/d twice daily from d1 to d14. The regimenwas given for 46 cycles, with 21 days in each cycle. Patient response and swallow status were evaluated after 2 cycles (6weeks). The effects and toxicity were assessed at 4 weeks after the chemotherapy regimen was completed. Results: The re-sponse rate was 76.3%(29/38) in the older group and 78.6%(33/42) in the control group (χ² =0.058, P>0.05). The rate ofswallow improvement was 86.8%(33/38) in the older group and 81.0% (34/42) in the control group (χ² =0.509, P>0.05).The efficacy was 78.9%(30/38) in the older group and 78.6%(33/42) in the control group (χ² =0.002, P>0.05). The toxicitywas similar and reversible in both groups (P>0.05). Conclusion: Combination chemotherapy of LOHP plus CAPE is aneffective, safe and welltolerated regimen for treating older patients with advanced GCA.